Universität Innsbruck
metadata only
CC BY 4.0
Selective cyclized peptide κ-opioid receptor antagonist - in vivo pharmacology
Modulating the GPCR k-opioid receptor is a promising strategy for treating CNS disorders, where the receptor antagonism is associated with beneficial effects for the treatment of mood and psychiatric diseases, and drug addictive disorders. Behavioral investigations in mice established the i
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Rational design of a Kappa opioid receptor peptide agonist with attenuated β-arrestin signaling.#297366
- Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence#812473
- Dopamine D2 Receptors, D1/D2 Receptor Heteromers and CaMKII Signaling in the Neurobiology of Drug Addiction.#244156
- Effects of Pentazocine on Manic Symptoms#1125103
- Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder#903955
Record · ID 1025386
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive